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AHI

:   apnea‐hypopnea index

BMI

:   body mass index

BP

:   blood pressure

CNS

:   central nervous system

CompSAS

:   complex sleep apnea syndromes

CPAP

:   continuous positive airway pressure

CSA

:   central sleep apnea

IBD

:   inflammatory bowel disease

IH

:   intermittent hypoxia

IL‐ 6

:   interleukin‐6

LPS

:   lipopolysaccharide

MAD

:   apnea‐hypopnea duration

MSA

:   mixed sleep apnea

NREM

:   non‐rapid eye movement

OSAHS

:   obstructive sleep apnea‐hypopnea syndrome

PCA

:   principal component analysis

PSG

:   polysomnography

REM

:   rapid eye movement

SAS

:   sleep apnea syndromes

SF

:   sleep fragmentation

TNF‐α

:   tumor necrosis factor alpha

1. INTRODUCTION {#brb31287-sec-0005}
===============

Intermittent hypoxia (IH) and sleep fragmentation (SF) are the hallmarks of obstructive sleep apnea‐hypopnea syndrome (OSAHS) (Moreno‐Indias et al., [2015](#brb31287-bib-0018){ref-type="ref"}, [2016](#brb31287-bib-0019){ref-type="ref"}; Poroyko et al., [2016](#brb31287-bib-0023){ref-type="ref"}). IH plays a critical pathophysiological role in of OSAHS, often accompanied by reduced oxygen saturation, increased systemic pressure and bloodstream, excessive sympathetic neural activity, impairment of autonomic function, and apnea episodes end with an arousal of the central nervous system (CNS), ultimately result in vascular endothelial dysfunction and multi‐organ morbid consequences. The underlying mechanism involves inflammation and oxidative stress cascades (Gaspar, Álvaro, Moita, & Cavadas, [2017](#brb31287-bib-0006){ref-type="ref"}; Lavie, [2015](#brb31287-bib-0015){ref-type="ref"}).

Contrastingly, sleep structure disruption is another risk factor for the pathophysiology of OSAHS, causing major end‐organ morbidity independent of IH (Rosenzweig, Williams, & Morrell, [2013](#brb31287-bib-0024){ref-type="ref"}, [2014](#brb31287-bib-0025){ref-type="ref"}). Repeated arousals disturbing different stages of sleep are the predominant mechanism underlying OSAHS‐induced brain injury wherein results from disruptions of rapid eye movement (REM) and non‐REM (NREM) (Rosenzweig, Williams, & Morrell, [2014](#brb31287-bib-0025){ref-type="ref"}). SF promotes obesity and metabolic abnormalities and may be mediated by concurrent alterations of the host gut microbiota and concurrent systemic and adipose tissue inflammatory alterations accompanied by insulin resistance (Farré, Farré, & Gozal, [2018](#brb31287-bib-0005){ref-type="ref"}; Poroyko et al., [2016](#brb31287-bib-0023){ref-type="ref"}). Reportedly, prolongation of the N1 stage and shortening of REM times were observed in OSAHS‐induced hypertensive patients; prolongation of the N1 sleep stage also causes elevation of fasting blood glucose (Shao et al., [2018](#brb31287-bib-0026){ref-type="ref"}). Elevated serum lipopolysaccharide (LPS)‐binding protein levels might prolong the N1 stage and increase SF, which may be related to increased nighttime respiratory events and arousals (Shao et al., [2018](#brb31287-bib-0026){ref-type="ref"}). Interestingly, disturbances in sleep continuity are associated with emotional disorders (Palagini, Baglioni, Ciapparelli, Gemignani, & Riemann, [2013](#brb31287-bib-0022){ref-type="ref"}); additionally, the disturbance of sleep structure also contributes to mild cognitive decline in OSAHS (Rosenzweig et al., [2014](#brb31287-bib-0025){ref-type="ref"}). However, treating OSAHS patients with continuous positive airway pressure (CPAP) has protective effects on neurocognition, postulated that the microbiota could be modulated during CPAP treatment (Xu et al., [2017](#brb31287-bib-0032){ref-type="ref"}), implying that the microbiota might participate in the pathophysiological developed mechanism.

Emerging evidence suggests that the gut microbiota plays a crucial role in modulating the risk of several chronic diseases and maintaining intestinal immunity and whole body homeostasis. These effects have important implications for diseases such as obesity, cardiometabolic abnormalities, inflammatory bowel disease (IBD), and mental illness (Singh et al., [2017](#brb31287-bib-0028){ref-type="ref"}). Additionally, the gut microbiota alterations manifested in IH and SF mimic in OSAHS animal models (Moreno‐Indias et al., [2015](#brb31287-bib-0018){ref-type="ref"}; Poroyko et al., [2016](#brb31287-bib-0023){ref-type="ref"}). However, some of the underlying mechanisms of OSAHS‐related comorbidities remain unclear. Enterotype analysis has been proposed as a useful method to understand human gut microbial communities, including *Bacteroides*, *Ruminococcus*, and *Prevotella* enterotypes, irrespective of ethnicity, gender, age, or body mass index (BMI) (Arumugam et al., [2011](#brb31287-bib-0001){ref-type="ref"}). Moreover, enterotypes subdivision provides an attractive framework for linking human disease. For example, *Bacteroides* enterotype has been reported to pose an increased risk for IBD (Conlon & Bird, [2015](#brb31287-bib-0003){ref-type="ref"}; Costea et al., [2018](#brb31287-bib-0004){ref-type="ref"}; Knights et al., [2014](#brb31287-bib-0013){ref-type="ref"}).

Notably, characteristics of IH and SF in OSAHS can trigger the inflammatory response, which then alters the intestinal microbial community composition (Moreno‐Indias et al., [2015](#brb31287-bib-0018){ref-type="ref"}; Palagini et al., [2013](#brb31287-bib-0022){ref-type="ref"}; Poroyko et al., [2016](#brb31287-bib-0023){ref-type="ref"}). Conversely, gut microbiomes can also respond to the brain via the microbiota--gut--brain axis, as has been declared in psychiatric disorders (Sherwin, Sandhu, Dinan, & Cryan, [2016](#brb31287-bib-0027){ref-type="ref"}). However, this hypothesis has not been verified for OSAHS. Thus, this study investigated the hypothesis that the microbiota--gut--brain axis is associated with the pathogenesis of OSAHS. We examined whether impaired sleep architecture is associated with gut microbiota alteration by investigating sleep parameters of polysomnography (PSG) data and pro‐inflammatory cytokines in various enterotypes of OSAHS subjects.

2. MATERIALS AND METHODS {#brb31287-sec-0006}
========================

2.1. Subjects {#brb31287-sec-0007}
-------------

In total, 113 subjects were recruited from July 2017 to January 2018, who were clinically suspicious with OSAHS and committed to sleep examination for the first time at sleep laboratory of Department of Pulmonary and Critical Care Medicine of the Second Affiliated Hospital of Fujian Medical University. Subjects with gastrointestinal diseases, infection, unexplained diarrhea, and antibiotics or probiotics used before recruitment around 1 month were excluded in this study. Subjects were examined during a full night of PSG (SOMNOscreen™ plus PSG^+^; SOMNOmedics GmbH, Randersacker, Germany) by technologists from 10 p.m. to 8 a.m. at the sleep laboratory. Fasting blood and fecal samples were collected the following morning. The Institutional Review Board of the Second Affiliated Hospital of Fujian Medical University approved this study (IRB No. 2017--78).

2.2. OSAHS evaluation {#brb31287-sec-0008}
---------------------

All the subjects underwent PSG with a computerized polysomnographic system, simultaneously including electrocardiography, electroencephalography, electromyography, and electrooculography. After one night of examination, apnea‐hypopnea index (AHI) was calculated as the total number of episodes of apnea (continuous cessation of airflow for at least 10 s) and hypopnea (reduction in airflow for ≥ 10 s with oxygen desaturation ≥4%) by dividing the total sleep by events. According to the diagnostic criteria, as reported previously studies (Heizati et al., [2017](#brb31287-bib-0009){ref-type="ref"}; Shao et al., [2018](#brb31287-bib-0026){ref-type="ref"}), AHI \< 15 events/h was defined as non‐OSAHS (control group) and AHI ≥ 15 events/h as OSAHS group.

2.3. Cytokine analysis {#brb31287-sec-0009}
----------------------

Interleukin (IL)‐6 and tumor necrosis factor alpha (TNF‐α) were assayed by BD Human Enhanced Sensitivity Cytometric Bead Array Kit (BD Biosciences, New Jersey, USA) as described previously (Kao, Ko, Wang, & Liu, [2016](#brb31287-bib-0010){ref-type="ref"}). The standard coefficient of determination (*r* ^2^) was greater than 0.995.

2.4. Sampling, DNA extraction, and 16S rRNA gene amplification sequencing {#brb31287-sec-0010}
-------------------------------------------------------------------------

Samples were collected and stored in a Microbiome Test Kit (G‐BIO Biotech, Inc., Hangzhou, China). Magnetic bead isolation was carried out to extract genomic DNA using a TIANamp stool DNA kit (TIANGEN Biotech Co., Ltd., Beijing, China), according to the manufacturer\'s instructions. The concentration of extracted DNA was determined by a Nanodrop ND‐1000 spectrophotometer (Thermo Electron Corporation, USA), and DNA quality was confirmed using 1.0% agarose gel electrophoresis with 0.5 mg/ml ethidium bromide.

Isolated fecal DNA was used as a template to amplify V3 and V4 hypervariable regions of the bacterial 16S ribosomal RNA gene. V3 and V4 regions were PCR‐amplified (forward primer, 5′‐ACTCCTACGGGAGGCAGCAG‐3′; reverse primer, 5′‐GGACTACHVGGGTWTCTAAT‐3′). The 16S target‐specific sequence contained adaptor sequences permitting uniform amplification of a highly complex library ready for downstream next‐generation sequencing on Illumina MiSeq (Illumina, USA). Negative DNA extraction controls (lysis buffer and kit reagents only) were amplified and sequenced as contamination controls. The amplicons were normalized, pooled, and sequenced on the Illumina MiSeq platform using a V3 reagent kit with 2 × 300 cycles per sample and with imported and prepared routine data (samsheet) run in the MiSeq sequence program. After sequencing, Q30 scores were ≥70%, the percentage of clusters passing filter (i.e., cluster PF) was ≥80%, and there were at least 30,000 clean tags. Finally, image analysis and base calling were conducted with MiSeq Control Software.

2.5. Bioinformatic, predictive function, and statistical analyses {#brb31287-sec-0011}
-----------------------------------------------------------------

Based on the Quantitative Insights into Microbial Ecology bio‐informatic pipeline for performing taxonomy assignment by the operational taxonomic unit method, we used data of 113 sequences to analyze the fecal microbiota taxa. We further analyzed between‐class analysis by the principal component analysis (PCA) and clustering basis of the genus compositions (Arumugam et al., [2011](#brb31287-bib-0001){ref-type="ref"}), utilizing R statistics. We performed other analyses using statistically with SPSS version 19.0 (SPSS Inc., Chicago, Illinois), data were expressed as the mean ± standard deviation (*SD*). For continuous variables that conformed to a normal distribution, the difference between groups was analyzed by *t* test or one‐way ANOVA. The significant differences within groups were analyzed using ANOVA followed by post‐hoc Fisher\'s least significant difference (LSD) corrections for multiple comparisons when the analysis of variance was significant. For continuous variables that were not normally distributed, the difference between groups was analyzed using H test. We considered a two‐sided *p*‐value of \< 0.05 to be statistically significant.

3. RESULTS {#brb31287-sec-0012}
==========

3.1. Patient characteristics and enterotype distribution {#brb31287-sec-0013}
--------------------------------------------------------

According to the PCA and clustering of fecal genus compositions for enterotypes class analysis, we enrolled 113 subjects \[non‐OSAHS (*n* = 61), OSAHS (*n* = 52)\] were divided according to three enterotypes: *Bacteroides* \[non‐OSAHS (*n* = 41), OSAHS (*n* = 32)\], *Ruminococcus* \[non‐OSAHS (*n* = 6), OSAHS (*n* = 8)\], and *Prevotella* \[non‐OSAHS (*n* = 14), OSAHS (*n* = 12)\] (Figure [1](#brb31287-fig-0001){ref-type="fig"}). Ages of *Ruminococcus* enterotype patients were significantly higher than those of the others enterotype patients (Table [1](#brb31287-tbl-0001){ref-type="table"}). BMI of *Prevotella* enterotype patients were significantly higher than *Bacteroides* enterotype patients (Table [1](#brb31287-tbl-0001){ref-type="table"}). The hip circumference of *Prevotella* enterotype patients were significantly higher than the others enterotype patients (Table [1](#brb31287-tbl-0001){ref-type="table"}).

![The fecal taxa class analysis in nonobstructive sleep apnoea--hypopnea syndrome (OSAHS) and OSAHS subjects of three enterotypes. Apnoea--hypopnea index (AHI) \<15 as non‐OSA, AHI ≥ 15 as OSA. Enterotype 1: *Bacteroides* \[non‐OSAHS (*n* = 41), OSAHS (*n* = 32)\], Enterotype 2: *Ruminococcus* \[non‐OSA (*n* = 6), OSAHS (*n* = 8)\], Enterotype 3: *Prevotella* \[non‐OSA (*n* = 14), OSAHS (*n* = 12)\]](BRB3-9-e01287-g001){#brb31287-fig-0001}

###### 

Participant characteristics

                               *Bacteroides*   *Ruminococcus*   *Prevotella*    *F* value                                   *p* Value   post‐hoc test             
  ---------------------------- --------------- ---------------- --------------- ------------------------------------------- ----------- --------------- --------- -------
  Gender (male/female)         61/12           11/3             20/6            NA[a](#brb31287-note-0004){ref-type="fn"}   NA          NA              NA        NA
  Age (years, mean ± *SD*)     40.89 ± 10.56   53.14 ± 14.37    44.58 ± 13.51   6.560                                       0.002       \<0.001         0.173     0.031
  Height (cm)                  166.28 ± 6.90   164.61 ± 7.30    166.83 ± 8.83   0.418                                       0.659       NA              NA        NA
  Weight (kg)                  72.51 ± 14.31   71.62 ± 14.25    79.41 ± 13.70   2.497                                       0.087       NA              NA        NA
  Body mass index (kg m^−2^)   26.11 ± 3.87    26.44 ± 5.50     28.73 ± 5.27    3.382                                       0.038       0.799           0.011     0.122
  Waist circumference (cm)     90.77 ± 9.87    91.21 ± 13.33    96.54 ± 12.27   2.742                                       0.069       NA              NA        NA
  Hip circumference (cm)       96.95 ± 6.03    97.75 ± 10.42    103.21 ± 8.97   6.920                                       0.001       0.712           \<0.001   0.028
  Waist‐to‐hip ratio           0.94 ± 0.07     0.93 ± 0.06      0.93 ± 0.06     0.290                                       0.749       NA              NA        NA

Values were calculated as mean ± *SD*.

Not analyzed.
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3.2. Cytokine analysis {#brb31287-sec-0014}
----------------------

There were not significantly different in IL‐ 6 and TNF‐α among three enterotypes patients (Figure [2](#brb31287-fig-0002){ref-type="fig"}).

![Cytokines levels analysis in three enterotypes subjects. IL: interleukin, TNF: tumor necrosis factor. Values were calculated as mean ± *SD*](BRB3-9-e01287-g002){#brb31287-fig-0002}

3.3. PSG parameter analysis {#brb31287-sec-0015}
---------------------------

Comparisons among patients with different enterotypes showed that total sleep arousal index was the lowest in the *Prevotella* enterotype patients (Table [2](#brb31287-tbl-0002){ref-type="table"}).

###### 

Polysomnographic data analysis in three enterotypes subjects

                                               *Bacteroides*     *Ruminococcus*    *Prevotella*      F/*χ* ^2^ value                                *p* value                                      post‐hoc test                                       
  -------------------------------------------- ----------------- ----------------- ----------------- ---------------------------------------------- ---------------------------------------------- ------------------------------------------- ------- -------
  Total sleep time (min)                       633.42 ± 58.95    648.78 ± 51.83    641.11 ± 44.60    2.128                                          0.124                                          NA[a](#brb31287-note-0006){ref-type="fn"}   NA      NA
  N1 sleep stage (min)                         138.56 ± 66.92    152.04 ± 82.37    171.62 ± 96.22    1.819                                          0.167                                          NA                                          NA      NA
  N1 sleep stage (%)                           36.10 ± 15.90     42.19 ± 14.54     39.76 ± 17.28     1.122                                          0.329                                          NA                                          NA      NA
  N2 sleep stage (min)                         111.30 ± 60.67    85.85 ± 44.25     111.94 ± 57.67    3.052[b](#brb31287-note-0007){ref-type="fn"}   0.217[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  N2 sleep stage (%)                           28.10 ± 11.99     24.45 ± 9.62      25.86 ± 10.48     0.814                                          0.446                                          NA                                          NA      NA
  N3 sleep stage (min)                         71.91 ± 36.85     57.71 ± 45.99     66.44 ± 41.66     0.839                                          0.435                                          NA                                          NA      NA
  N3 sleep stage (%)                           18.33 ± 8.29      15.95 ± 10.23     16.25 ± 9.79      0.790                                          0.456                                          NA                                          NA      NA
  Non‐rapid eye movement (NREM) (min)          321.79 ± 87.88    295.60 ± 96.74    350.01 ± 98.5     1.740                                          0.180                                          NA                                          NA      NA
  NREM (%)                                     82.56 ± 10.84     82.57 ± 7.62      81.87 ± 9.88      0.045                                          0.956                                          NA                                          NA      NA
  Rapid eye movement (REM) (min)               67.21 ± 43.27     67.17 ± 37.26     79.63 ± 44.02     0.844                                          0.433                                          NA                                          NA      NA
  REM (%)                                      17.43 ± 10.84     17.42 ± 7.62      18.12 ± 9.88      0.046                                          0.955                                          NA                                          NA      NA
  Sleep efficiency (%)                         70.40 ± 14.99     64.62 ± 21.45     75.92 ± 18.36     2.203                                          0.115                                          NA                                          NA      NA
  Sleep latency                                31.0 ± 29.96      31.7 ± 29.97      18.93 ± 20.36     4.726[b](#brb31287-note-0007){ref-type="fn"}   0.094[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Wake after sleep onset                       129.91 ± 71.69    174.76 ± 116.12   110.50 ± 98.33    2.643                                          0.076                                          NA                                          NA      NA
  Arousal time (min)                           157.64 ± 78.71    202.23 ± 131.03   128.14 ± 100.46   3.001                                          0.054                                          NA                                          NA      NA
  Arousal times                                20.35 ± 11.57     19.64 ± 12.70     14.50 ± 9.36      2.631                                          0.077                                          NA                                          NA      NA
  Arousal index (events/h)                     3.34 ± 2.06       3.86 ± 3.19       2.30 ± 1.68       3.087                                          0.050                                          0.414                                       0.036   0.031
  Arousal time in REM                          39.93 ± 38.94     39.42 ± 34.74     52.00 ± 36.13     3.870[b](#brb31287-note-0007){ref-type="fn"}   0.144[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Arousal index in REM                         32.25 ± 16.44     29.52 ± 17.66     38.96 ± 16.29     2.026                                          0.137                                          NA                                          NA      NA
  Arousal time in NREM                         210.15 ± 126.03   209.57 ± 148.79   288.19 ± 226.67   1.413[b](#brb31287-note-0007){ref-type="fn"}   0.493[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Arousal index in NREM                        38.17 ± 15.54     39.98 ± 16.20     45.76 ± 26.09     0.386[b](#brb31287-note-0007){ref-type="fn"}   0.824[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Total sleep arousal times                    250.08 ± 136.58   249.00 ± 166.24   340.19 ± 249.89   1.843[b](#brb31287-note-0007){ref-type="fn"}   0.398[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Total sleep arousal index                    38.06 ± 15.18     38.75 ± 15.83     44.64 ± 24.15     0.342[b](#brb31287-note-0007){ref-type="fn"}   0.843[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Apnea‐hypopnea index (events/h)              19.63 ± 21.42     27.90 ± 22.63     27.41 ± 30.96     2.285[b](#brb31287-note-0007){ref-type="fn"}   0.319[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Apnea‐hypopnea times                         132.19 ± 170.66   180.50 ± 176.90   221.34 ± 278.37   1.627[b](#brb31287-note-0007){ref-type="fn"}   0.443[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Obstructive apnea index (events/h)           8.85 ± 15.04      10.88 ± 12.44     10.62 ± 16.09     2.787[b](#brb31287-note-0007){ref-type="fn"}   0.248[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Obstructive apnea times                      62.78 ± 120.68    71.28 ± 102.99    85.26 ± 134.75    1.854[b](#brb31287-note-0007){ref-type="fn"}   0.396[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Central apnea index (events/h)               0.46 ± 1.29       2.75 ± 8.64       1.92 ± 4.04       0.694[b](#brb31287-note-0007){ref-type="fn"}   0.707[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Central apnea times                          3.39 ± 9.45       11.78 ± 31.62     17.5 ± 40.21      0.778[b](#brb31287-note-0007){ref-type="fn"}   0.678[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Mixed apnea index (events/h)                 0.59 ± 1.52       1.61 ± 3.80       2.88 ± 6.79       1.664[b](#brb31287-note-0007){ref-type="fn"}   0.435[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Mixed apnea times                            4.56 ± 13.25      10.5 ± 27.95      25.73 ± 64.80     1.768[b](#brb31287-note-0007){ref-type="fn"}   0.413[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Hypopnea index (events/h)                    9.71 ± 8.95       12.63 ± 17.71     11.98 ± 14.29     0.036[b](#brb31287-note-0007){ref-type="fn"}   0.982[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Hypopnea times                               61.45 ± 55.31     86.92 ± 136.55    92.84 ± 125.09    0.388[b](#brb31287-note-0007){ref-type="fn"}   0.824[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Longest apnea time (s)                       37.80 ± 23.24     46.64 ± 27.65     45.26 ± 38.39     1.312[b](#brb31287-note-0007){ref-type="fn"}   0.519[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Mean apnea‐hypopnea duration (s)             19.55 ± 8.98      20.25 ± 8.28      20.01 ± 9.78      0.049                                          0.952                                          NA                                          NA      NA
  Longest hypopnea time (s)                    68.26 ± 33.06     66.85 ± 27.29     78.50 ± 32.89     1.056                                          0.351                                          NA                                          NA      NA
  Average hypopnea time (s)                    28.3 ± 9.95       29.75 ± 12.62     31.52 ± 8.38      1.021                                          0.364                                          NA                                          NA      NA
  Oxygen desaturation index (events/h)         18.72 ± 20.79     25.22 ± 23.56     25.9 ± 29.82      1.362[b](#brb31287-note-0007){ref-type="fn"}   0.506[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Lowest oxygen saturation (%)                 82.26 ± 8.81      79.35 ± 9.34      82.23 ± 10.88     0.584                                          0.559                                          NA                                          NA      NA
  Average oxygen saturation (%)                94.34 ± 2.04      93.92 ± 3.34      94.15 ± 2.66      0.204                                          0.816                                          NA                                          NA      NA
  Longest oxygen desaturation (s)              109.16 ± 42.98    95.17 ± 28.61     99.51 ± 40.54     1.011                                          0.367                                          NA                                          NA      NA
  Mean heart rate                              65.95 ± 10.32     65 ± 7.93         63.73 ± 9.55      0.495                                          0.611                                          NA                                          NA      NA
  Arrhythmia index (events/h)                  12.89 ± 54.36     38.04 ± 134.47    4.23 ± 8.19       1.428[b](#brb31287-note-0007){ref-type="fn"}   0.490[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Maximum heart rate                           99.41 ± 15.06     97.28 ± 12.19     96.92 ± 16.70     0.760[b](#brb31287-note-0007){ref-type="fn"}   0.684[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  Minimum heart rate                           51.67 ± 8.97      53.28 ± 5.21      51.53 ± 6.68      0.255                                          0.775                                          NA                                          NA      NA
  Blood pressure elevation index (events/h)    13.22 ± 15.21     16.43 ± 15.52     16.58 ± 22.43     0.757[b](#brb31287-note-0007){ref-type="fn"}   0.685[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA
  The highest systolic blood pressure (mmHg)   157.98 ± 39.08    148.57 ± 58.14    158.8 ± 45.51     0.308                                          0.736                                          NA                                          NA      NA
  Average systolic blood pressure (mmHg)       120.41 ± 25.98    113.78 ± 42.26    118.19 ± 28.64    0.323                                          0.725                                          NA                                          NA      NA
  Average diastolic blood pressure (mmHg)      81.80 ± 16.05     77.21 ± 24.46     82.92 ± 21.59     0.814[b](#brb31287-note-0007){ref-type="fn"}   0.666[b](#brb31287-note-0007){ref-type="fn"}   NA                                          NA      NA

Values were calculated as mean ± *SD*.

Not analyzed.

Because the data do not meet the requirements of variance test, displayed as the Chi‐square test corresponding to the H test.

John Wiley & Sons, Ltd

Using 15 as the AHI cutoff, when AHI ≥ 15, N1 sleep stage, arousal time in REM, and arousal index in REM were the highest in the *Prevotella* enterotype patients. Contrastingly, sleep latency and arousal time were the lowest in the *Prevotella* enterotype patients (Table [3](#brb31287-tbl-0003){ref-type="table"}).

###### 

Polysomnographic data analysis in three enterotypes of apnoea--hypopnea index ≥ 15 patients

                                               *Bacteroides*     *Ruminococcus*    *Prevotella*      F/*χ* ^2^ value                                 *p* value                                      post‐hoc test                                       
  -------------------------------------------- ----------------- ----------------- ----------------- ----------------------------------------------- ---------------------------------------------- ------------------------------------------- ------- -------
  Total sleep time (min)                       632.59 ± 71.61    663.63 ± 45.48    639.25 ± 41.52    1.803                                           0.176                                          NA[a](#brb31287-note-0009){ref-type="fn"}   NA      NA
  N1 sleep stage (min)                         162.46 ± 71.21    159.70 ± 98.14    236.23 ± 102.31   3.681                                           0.032                                          0.934                                       0.012   0.050
  N1 sleep stage (%)                           41.93 ± 15.78     41.18 ± 17.37     50.03 ± 16.75     1.199                                           0.310                                          NA                                          NA      NA
  N2 sleep stage (min)                         111.86 ± 65.07    95.24 ± 48.56     101.92 ± 56.09    0.292                                           0.748                                          NA                                          NA      NA
  N2 sleep stage (%)                           27.65 ± 11.46     24.23 ± 8.41      22.03 ± 9.76      1.308                                           0.280                                          NA                                          NA      NA
  N3 sleep stage (min)                         61.95 ± 35.56     63.06 ± 55.27     45.71 ± 37.88     0.805                                           0.453                                          NA                                          NA      NA
  N3 sleep stage (%)                           15.61 ± 7.96      16.54 ± 12.79     9.90 ± 7.97       2.101                                           0.133                                          NA                                          NA      NA
  Non‐rapid eye movement (NREM) (min)          336.27 ± 92.94    318.00 ± 102.04   383.86 ± 111.29   1.355                                           0.267                                          NA                                          NA      NA
  NREM (%)                                     85.20 ± 10.65     81.94 ± 5.83      81.96 ± 10.05     0.655                                           0.524                                          NA                                          NA      NA
  Rapid eye movement (REM) (min)               56.65 ± 38.27     69.61 ± 33.06     76.83 ± 29.52     1.538                                           0.225                                          NA                                          NA      NA
  REM (%)                                      14.80 ± 10.65     18.06 ± 5.83      18.04 ± 10.05     0.655                                           0.524                                          NA                                          NA      NA
  Sleep efficiency (%)                         70.68 ± 15.53     68.66 ± 19.05     81.52 ± 16.78     2.227                                           0.119                                          NA                                          NA      NA
  Sleep latency                                28.21 ± 26.64     26.26 ± 15.89     7.93 ± 5.48       12.911[b](#brb31287-note-0010){ref-type="fn"}   0.002[b](#brb31287-note-0010){ref-type="fn"}   0.703                                       0.001   0.005
  Wake after sleep onset                       131.92 ± 74.80    156.49 ± 119.11   77.79 ± 46.87     2.974                                           0.060                                          NA                                          NA      NA
  Arousal time (min)                           156.51 ± 76.52    177.55 ± 118.32   84.31 ± 48.77     4.547                                           0.015                                          0.504                                       0.009   0.013
  Arousal times                                19.34 ± 12.06     19.75 ± 14.53     12.50 ± 10.70     1.501                                           0.233                                          NA                                          NA      NA
  Arousal index (events/h)                     3.35 ± 2.52       3.89 ± 4.09       1.89 ± 1.83       1.713                                           0.191                                          NA                                          NA      NA
  Arousal time in REM                          34.81 ± 29.91     43.00 ± 34.32     66.67 ± 39.80     4.064                                           0.023                                          0.533                                       0.006   0.123
  Arousal index in REM                         33.37 ± 18.93     34.26 ± 17.70     50.00 ± 13.49     4.011                                           0.024                                          0.898                                       0.008   0.057
  Arousal time in NREM                         260.28 ± 152.59   262.13 ± 178.51   433.25 ± 262.42   4.190[b](#brb31287-note-0010){ref-type="fn"}    0.123[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Arousal index in NREM                        45.67 ± 17.02     46.20 ± 18.56     63.53 ± 28.16     3.491[b](#brb31287-note-0010){ref-type="fn"}    0.175[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Total sleep arousal times                    295.09 ± 160.4    305.13 ± 194.43   499.92 ± 285.72   4.389[b](#brb31287-note-0010){ref-type="fn"}    0.111[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Total sleep arousal index                    44.99 ± 16.94     44.41 ± 18.55     61.68 ± 25.41     3.919[b](#brb31287-note-0010){ref-type="fn"}    0.141[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Apnea‐hypopnea index (events/h)              36.39 ± 22.86     42.04 ± 19.98     52.53 ± 29.78     3.884[b](#brb31287-note-0010){ref-type="fn"}    0.143[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Apnea‐hypopnea times                         247.09 ± 204.93   278.88 ± 176.82   430.58 ± 294.38   3.641[b](#brb31287-note-0010){ref-type="fn"}    0.162[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Obstructive apnea index (events/h)           18.03 ± 19.14     14.43 ± 15.52     21.38 ± 18.74     0.560[b](#brb31287-note-0010){ref-type="fn"}    0.756[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Obstructive apnea times                      129.47 ± 159.54   99.88 ± 129.97    173.25 ± 159.52   1.534[b](#brb31287-note-0010){ref-type="fn"}    0.465[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Central apnea index (events/h)               0.98 ± 1.83       4.81 ± 11.28      3.83 ± 5.40       0.731 [b](#brb31287-note-0010){ref-type="fn"}   0.694[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Central apnea times                          7.09 ± 13.44      20.63 ± 40.61     35.50 ± 54.65     0.578[b](#brb31287-note-0010){ref-type="fn"}    0.749[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Mixed apnea index (events/h)                 1.31 ± 2.10       2.78 ± 4.81       6.19 ± 9.08       1.852[b](#brb31287-note-0010){ref-type="fn"}    0.396[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Mixed apnea times                            10.13 ± 18.71     18.13 ± 36.00     55.33 ± 88.13     2.091[b](#brb31287-note-0010){ref-type="fn"}    0.351[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Hypopnea index (events/h)                    16.08 ± 9.56      19.99 ± 20.79     21.17 ± 16.88     0.734                                           0.485                                          NA                                          NA      NA
  Hypopnea times                               100.41 ± 57.37    140.25 ± 163.59   166.50 ± 155.08   0.977[b](#brb31287-note-0010){ref-type="fn"}    0.614[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Longest apnea time (s)                       50.31 ± 19.59     47.63 ± 29.34     69.08 ± 38.55     2.494                                           0.093                                          NA                                          NA      NA
  Mean apnea‐hypopnea duration (s)             23.20 ± 6.35      20.30 ± 6.90      26.97 ± 7.53      2.531                                           0.090                                          NA                                          NA      NA
  Longest hypopnea time (s)                    82.69 ± 28.53     70.25 ± 25.97     99.75 ± 24.15     3.044                                           0.057                                          NA                                          NA      NA
  Average hypopnea time (s)                    31.29 ± 6.58      28.53 ± 6.55      35.74 ± 8.24      2.871                                           0.066                                          NA                                          NA      NA
  Oxygen desaturation index (events/h)         34.23 ± 22.94     38.98 ± 22.58     49.73 ± 29.24     1.758                                           0.183                                          NA                                          NA      NA
  Lowest oxygen saturation (%)                 76.31 ± 9.20      76.00 ± 10.01     74.83 ± 12.04     0.095                                           0.909                                          NA                                          NA      NA
  Average oxygen saturation (%)                93.31 ± 2.32      93.13 ± 4.09      92.50 ± 2.81      1.111[b](#brb31287-note-0010){ref-type="fn"}    0.574[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Longest oxygen desaturation (s)              113.18 ± 37.43    103.39 ± 23.54    92.93 ± 26.57     1.646                                           0.203                                          NA                                          NA      NA
  Mean heart rate                              66.56 ± 10.38     67.25 ± 6.67      67.83 ± 10.83     0.074                                           0.929                                          NA                                          NA      NA
  Arrhythmia index (events/h)                  5.29 ± 13.97      65.06 ± 177.85    3.82 ± 5.03       0.784[b](#brb31287-note-0010){ref-type="fn"}    0.676[b](#brb31287-note-0010){ref-type="fn"}   NA                                          NA      NA
  Maximum heart rate                           99.09 ± 14.79     99.75 ± 15.64     103.08 ± 18.70    0.278                                           0.758                                          NA                                          NA      NA
  Minimum heart rate                           51.88 ± 7.07      54.50 ± 4.44      53.50 ± 6.56      0.626                                           0.539                                          NA                                          NA      NA
  Blood pressure elevation index (events/h)    20.91 ± 18.96     20.44 ± 18.45     26.09 ± 27.79     0.288                                           0.751                                          NA                                          NA      NA
  The highest systolic blood pressure (mmHg)   172.97 ± 35.54    180.75 ± 38.26    163.25 ± 62.49    0.414                                           0.663                                          NA                                          NA      NA
  Average systolic blood pressure (mmHg)       130.44 ± 22.64    138.50 ± 22.91    117.58 ± 41.10    1.508                                           0.231                                          NA                                          NA      NA
  Average diastolic blood pressure (mmHg)      87.28 ± 13.38     88.00 ± 9.94      84.25 ± 29.45     0.150                                           0.861                                          NA                                          NA      NA

Values were calculated as mean ± *SD*.

Not analyzed.

Because the data do not meet the requirements of variance test, displayed as the Chi‐square test corresponding to the H test.
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For *Prevotella* enterotype patients, N1 sleep stage, N3 sleep stage, arousal index in REM, arousal time in NREM, arousal index in NREM, total sleep arousal times, total sleep arousal index, AHI, apnea‐hypopnea times, obstructive apnea index, obstructive apnea times, central apnea index, mixed apnea index, hypopnea index, hypopnea times, longest apnea time, mean apnea‐hypopnea duration (MAD), longest hypopnea time, average hypopnea time, oxygen desaturation index, and mean heart rate were significantly elevated in AHI ≥ 15 patients. However, sleep latency, arousal time, lowest oxygen saturation, and average oxygen saturation were significantly decreased in AHI ≥ 15 patients (Table [4](#brb31287-tbl-0004){ref-type="table"}).

###### 

Polysomnographic data analysis in *Prevotella* enterotype subjects

                                               AHI ＜15              AHI ≥ 15
  -------------------------------------------- --------------------- ----------------------------------------------------------------
  Total sleep time (min)                       403.04 ± 118.21       460.69 ± 117.35
  N1 sleep stage (min)                         **116.25 ± 42.34**    **236.23 ± 102.31** [\*\*](#brb31287-note-0014){ref-type="fn"}
  N1 sleep stage (%)                           **30.96 ± 12.49**     **50.03 ± 16.75** [\*\*](#brb31287-note-0014){ref-type="fn"}
  N2 sleep stage (min)                         120.54 ± 59.68        101.92 ± 56.09
  N2 sleep stage (%)                           29.15 ± 10.26         22.03 ± 9.76
  N3 sleep stage (min)                         **84.21 ± 37.23**     **45.71 ± 37.88** [\*](#brb31287-note-0013){ref-type="fn"}
  N3 sleep stage (%)                           **21.70 ± 7.83**      **9.90 ± 7.97** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Non‐rapid eye movement (NREM) (min)          321.00 ± 78.85        383.86 ± 111.29
  NREM (%)                                     81.80 ± 10.11         81.96 ± 10.05
  Rapid eye movement (REM) (min)               82.04 ± 54.54         76.83 ± 29.52
  REM (%)                                      18.20 ± 10.11         18.04 ± 10.05
  Sleep efficiency (%)                         71.13 ± 18.87         81.52 ± 16.78
  Sleep latency                                **28.36 ± 23.75**     **7.93 ± 5.48** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Wake after sleep onset                       138.54 ± 122.07       77.79 ± 46.87
  Arousal time (min)                           **165.71 ± 118.75**   **84.31 ± 48.77** [\*](#brb31287-note-0013){ref-type="fn"}
  Arousal times                                16.21 ± 8.06          12.50 ± 10.70
  Arousal index (events/h)                     2.66 ± 1.52           1.89 ± 1.83
  Arousal time in REM                          39.43 ± 28.30         66.67 ± 39.80
  Arousal index in REM                         **29.50 ± 12.13**     **50.00 ± 13.49** [\*\*\*](#brb31287-note-0015){ref-type="fn"}
  Arousal time in NREM                         **163.86 ± 66.82**    **433.25 ± 262.42** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Arousal index in NREM                        **30.54 ± 9.82**      **63.53 ± 28.16** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Total sleep arousal times                    **203.29 ± 85.31**    **499.92 ± 285.72** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Total sleep arousal index                    **30.04 ± 8.81**      **61.68 ± 25.41** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Apnea‐hypopnea index (events/h)              **5.88 ± 3.43**       **52.53 ± 29.78** [\*\*\*](#brb31287-note-0015){ref-type="fn"}
  Apnea‐hypopnea times                         **42.00 ± 25.31**     **430.58 ± 294.38** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Obstructive apnea index (events/h)           **1.41 ± 1.65**       **21.38 ± 18.74** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Obstructive apnea times                      **9.86 ± 10.79**      **173.25 ± 159.52** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Central apnea index (events/h)               **0.30 ± 0.77**       **3.83 ± 5.40** [\*](#brb31287-note-0013){ref-type="fn"}
  Central apnea times                          2.07 ± 5.14           35.50 ± 54.65
  Mixed apnea index (events/h)                 **0.05 ± 0.09**       **6.19 ± 9.08** [\*](#brb31287-note-0013){ref-type="fn"}
  Mixed apnea times                            0.36 ± 0.63           55.33 ± 88.13
  Hypopnea index (events/h)                    **4.11 ± 2.65**       **21.17 ± 16.88** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Hypopnea times                               **29.71 ± 21.00**     **166.50 ± 155.08** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Longest apnea time (s)                       **24.86 ± 24.59**     **69.08 ± 38.55** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Mean apnea‐hypopnea duration (s)             **14.06 ± 7.29**      **26.97 ± 7.53** [\*\*\*](#brb31287-note-0015){ref-type="fn"}
  Longest hypopnea time (s)                    **60.29 ± 28.51**     **99.75 ± 24.15** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Average hypopnea time (s)                    **27.91 ± 6.86**      **35.74 ± 8.24** [\*](#brb31287-note-0013){ref-type="fn"}
  Oxygen desaturation index (events/h)         **5.48 ± 3.66**       **49.73 ± 29.24** [\*\*\*](#brb31287-note-0015){ref-type="fn"}
  Lowest oxygen saturation (%)                 **88.57 ± 3.34**      **74.83 ± 12.04** [\*\*\*](#brb31287-note-0015){ref-type="fn"}
  Average oxygen saturation (%)                **95.00 ± 1.79**      **92.50 ± 2.81** [\*\*](#brb31287-note-0014){ref-type="fn"}
  Longest oxygen desaturation (s)              84.23 ± 33.17         92.93 ± 26.57
  Mean heart rate                              **62.00 ± 9.08**      **67.83 ± 10.83** [\*](#brb31287-note-0013){ref-type="fn"}
  Arrhythmia index (events/h)                  2.02 ± 2.09           3.82 ± 5.03
  Maximum heart rate                           94.00 ± 4.60          103.08 ± 18.70
  Minimum heart rate                           51.67 ± 6.12          53.50 ± 6.56
  Blood pressure elevation index (events/h)    11.10 ± 9.49          26.09 ± 27.79
  The highest systolic blood pressure (mmHg)   105.67 ± 53.60        163.25 ± 62.49
  Average systolic blood pressure (mmHg)       80.83 ± 40.36         117.58 ± 41.10
  Average diastolic blood pressure (mmHg)      62.83 ± 31.35         84.25 ± 29.45

Values were calculated as mean ± *SD*.

AHI: apnoea--hypopnea index.

*p* \< 0.05,

*p* \< 0.01,

*p* \< 0.001 compared with AHI \< 15 subjects.
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4. DISCUSSION {#brb31287-sec-0016}
=============

OSAHS is a systemic and comprehensive disorder associated with comorbidities, including cardiovascular diseases and metabolic abnormalities. Thus, the IH mechanism alone is insufficient to interpret the complete pathogenesis of OSAHS because OSAHS is also affected by several other aspects, including the CNS causing neuropsychiatric and neurodegenerative disorders (Farré et al., [2018](#brb31287-bib-0005){ref-type="ref"}; Gaspar et al., [2017](#brb31287-bib-0006){ref-type="ref"}; Lavie, [2015](#brb31287-bib-0015){ref-type="ref"}; Rosenzweig et al., [2014](#brb31287-bib-0025){ref-type="ref"}). This study shows that arousal‐related parameters or sleep stages are significantly disrupted in AHI ≥ 15 patients with *Prevotella* enterotypes; further analysis, obstructive, central, and mixed apnea indices, and mean heart rate are also significantly elevated in AHI ≥ 15 patients.

*Prevotella* enterotype is associated with diets high in carbohydrates (fiber) and simple sugars. *Bacteroides* enterotype is associated with Western‐style diets, including consuming high amounts of protein and fat, whereas *Ruminococcus* species enterotype is linked to nondigestible carbohydrates (Conlon & Bird, [2015](#brb31287-bib-0003){ref-type="ref"}). Despite the fact that the *Bacteroides* predominant enterotype seems to be more common in IBD patients, the *Prevotella* enterotype is more representative in healthy subjects (Costea et al., [2018](#brb31287-bib-0004){ref-type="ref"}; Knights et al., [2014](#brb31287-bib-0013){ref-type="ref"}). Our findings show that *Bacteroides* enterotype patients are not susceptible to OSAHS, in contrast to the susceptibility of *Prevotella* enterotype patients.

IH‐exposed mice mimic OSAHS, causing profound alterations in gut microbiota. Hypoxia/re‐oxygenation is the most pronounced (Moreno‐Indias et al., [2015](#brb31287-bib-0018){ref-type="ref"}), inducing an alteration in intestinal epithelial barrier markers and increasing intestinal permeability, leading to local and systemic inflammatory responses and consequent multi‐organ morbidities (Barceló et al., [2016](#brb31287-bib-0002){ref-type="ref"}; Grootjans et al., [2010](#brb31287-bib-0008){ref-type="ref"}). However, only *Bacteroides* and *Prevotella* enterotypes can be classified in the rodent model, IH‐exposed mice classify as the *Prevotella* enterotype (Moreno‐Indias et al., [2015](#brb31287-bib-0018){ref-type="ref"}), which is similar to our particularly OSAHS patients. It has further been shown that IH leads to gut microbiota alteration and accompanying endotoxin production (Maes, Kubera, & Leunis, [2008](#brb31287-bib-0017){ref-type="ref"}). It is that IH model creates an anoxic environment in the intestine, which is beneficial for obligate anerobic bacterial growth, endogenous LPS production from gram‐negative bacteria, and triggering inflammation. Notably, *Prevotella* is a genus of gram‐negative anerobic bacteria, and it has a tendency to alter intestinal permeability (Moreno‐Indias et al., [2015](#brb31287-bib-0018){ref-type="ref"}, [2016](#brb31287-bib-0019){ref-type="ref"}). Although this evidence only reveals the IH contribution to the pathogenesis, we also speculated that SF is another principal contributor (Poroyko et al., [2016](#brb31287-bib-0023){ref-type="ref"}). SF‐induced mice manifest inflammation and enhanced production of endotoxins produced by gut microbiota, too (Poroyko et al., [2016](#brb31287-bib-0023){ref-type="ref"}). Taken together, LPS may play a crucial role in driving systemic inflammation, it has been shown in IH and SF modeling OSAHS models (Moreno‐Indias et al., [2015](#brb31287-bib-0018){ref-type="ref"}, [2016](#brb31287-bib-0019){ref-type="ref"}; Poroyko et al., [2016](#brb31287-bib-0023){ref-type="ref"}). Moreover, in middle‐aged non‐obese males with OSAHS, disruption of the intestinal barrier, and concurrent increased serum d‐lactate levels possibly contribute to intestinal hyperpermeability and are significantly positively associated with pro‐inflammatory IL‐1β, IL‐6, and TNF‐α cytokines in serum (Heizati et al., [2017](#brb31287-bib-0009){ref-type="ref"}) in which TNF‐α elevation in *Prevotella* enterotype subjects is similar with our results, but it did not reach statistically significant differences.

*Prevotella* enterotype patients with AHI ≥ 15 in our results, suggesting that LPS production triggers downstream signaling pathways, leading to the subsequent release of pro‐inflammatory cytokines (Tobias, Soldau, & Ulevitch, [1989](#brb31287-bib-0029){ref-type="ref"}). Furthermore, the elevation of LPS‐binding protein is also verified in OSAHS mimicking rodent models (Poroyko et al., [2016](#brb31287-bib-0023){ref-type="ref"}) and patients (Heizati et al., [2017](#brb31287-bib-0009){ref-type="ref"}), particularly regarding in the higher d‐lactate level of OSAHS patients. Inflammatory mediators can be produced by peripheral and central cells. Peripheral inflammatory mediators may invade the CNS by crossing the blood--brain barrier, affecting behaviors and causing metabolic problems and psychiatric disorders (Ko & Liu, [2016](#brb31287-bib-0014){ref-type="ref"}). Here, our data suggest that the gut microbiota might impact the brain in OSAHS patients by modulating inflammatory responses.

Additionally, we should mention that the *Prevotella* enterotype is linked to diets rich in simple sugars. Simple carbohydrate consumption has been hypothesized to be related to elevated BP values and obesity (Orlando, Cazzaniga, Giussani, Palestini, & Genovesi, [2018](#brb31287-bib-0021){ref-type="ref"}), as showed in our data. *Prevotella* enterotype patients had a higher BMI and hip circumference than *Bacteriodes* enterotype patients. Monosaccharide intake induces inflammation in epithelial cells and contributes to hypertension (Orlando et al., [2018](#brb31287-bib-0021){ref-type="ref"}), linking to LPS production, which can stimulate systemic inflammatory cascades (Moreno‐Indias et al., [2015](#brb31287-bib-0018){ref-type="ref"}). Inflammation mediates the pathogenesis of many physiological dysfunctions, such as metabolic syndrome and mental dysfunction (Ko & Liu, [2016](#brb31287-bib-0014){ref-type="ref"}), and thus might ultimately result in OSAHS‐related metabolic comorbidities. Although *Ruminococcus* is associated with resistant starch, host health benefits from short chain fatty acids that have been demonstrated to regulate immune inflammatory responses (Macfarlane & Macfarlane, [2012](#brb31287-bib-0016){ref-type="ref"}). The enriched bacteria *Ruminococcus* spp. and *Sutterella* spp. are found in psychiatric patients (Wang et al., [2013](#brb31287-bib-0030){ref-type="ref"}). The abovementioned literature supports the hypothesis that microbiota disruption influences the pathophysiological process of OSAHS might be through a microbiota--gut--brain axis.

Despite OSAHS is one of the most common sleep apnea syndromes (SAS), other types are mixed sleep apnea (MSA) and central sleep apnea (CSA). The prevalence of OSAHS, complex SAS (CompSAS), and central SAS are 84.0%, 15.0%, and 0.4%, respectively (Morgenthaler, Kagramanov, Hanak, & Decker, [2006](#brb31287-bib-0020){ref-type="ref"}). MSA generally describes the mixture of both obstructive and central apnea events during diagnostic sleep, although many central apnea indices occurrence is also identified as MSA, which is sometimes referred to as CompSAS (Khan & Franco, [2014](#brb31287-bib-0011){ref-type="ref"}). Whereas CompSAS is a form of CAS wherein the persistence or emergence of central apneas or hypopneas has disappeared with CPAP, patients have predominately obstructive or mixed apneas occurring at ≥ 5 events/h (Gay, [2008](#brb31287-bib-0007){ref-type="ref"}). Additionally, reportedly, there is a high prevalence of hypertension and heart disease in patients with CompSAS (Westhoff, Arzt, & Litterst, [2012](#brb31287-bib-0031){ref-type="ref"}). In our data, all of apnea indices were significantly increased in *Prevotella* enterotype patients with AHI ≥ 15. Thus, abnormalities in electrocardiography, electroencephalography, electromyography, and electro‐oculography results should be more concern.

Both IH and SF have been demonstrated to independently affect similar CNS regions in animal research (Rosenzweig et al., [2014](#brb31287-bib-0025){ref-type="ref"}). The N1 sleep stage is associated with the transition from wakefulness to other sleep stages or the following arousal during sleep. A higher N1 percentage might mean more events of wakefulness and/or arousal, SF (episodic arousal from sleep), and sympathetic overactivity during sleep (Shao et al., [2018](#brb31287-bib-0026){ref-type="ref"}). REM sleep dysregulation significantly contributes to cognitive distortions and dysfunctions that rely on emotion and memory functions are also affected (Palagini et al., [2013](#brb31287-bib-0022){ref-type="ref"}). Moreover, the effects of sleep deprivation on cognition have been investigated (Killgore, [2010](#brb31287-bib-0012){ref-type="ref"}). Thus, OSAHS patients have been found to have neurocognitive and emotional disorders, suggesting the modulation of various neurotransmitters during the sleep period (Rosenzweig et al., [2014](#brb31287-bib-0025){ref-type="ref"}). Recently, a multicenter randomized controlled trial has been initiated evaluating the extent to which CPAP treatment improves neurocognitive dysfunction in OSAHS patients and examining the role of gut microbiota in this change (Xu et al., [2017](#brb31287-bib-0032){ref-type="ref"}). Preliminary results suggest the viability of the hypothesis that microbiota modulate central nervous functions in OSAHS patients.

Although the neural mechanisms underlying SAS‐induced brain injury have not been completely elucidated, repeated arousals enable the characterization of the different stages of sleep. In this study, the N1 sleep stage, MAD, and arousal index were increased in *Prevotella* enterotype patients. BP was not significantly different among the three enterotype AHI ≥ 15 patient groups, but mean diastolic pressure during sleep was \> 80 mmHg, which was similar to that observed in a previous study (Shao et al., [2018](#brb31287-bib-0026){ref-type="ref"}). MAD can act as an indicator of the levels of sleep parameters and blood oxygenation for the evaluation of severe OSAHS patients (Zhan, Fang, Wu, Pinto, & Wei, [2018](#brb31287-bib-0033){ref-type="ref"}). When MAD is elevated, sleep apnea appears to be more likely to cause respiratory arousal and might impair sleep stability, resulting in SF. This outcome might then be that the transition of the N2 sleep stage (the longest stage of sleep) to the N3 sleep stage is a vulnerable period, which is interrupted in OSAHS patients, and the overall sleep pattern becomes light sleep (Zhan et al., [2018](#brb31287-bib-0033){ref-type="ref"}). Additionally, chronic SF induction elevates fat mass, alters fecal microbiota, promotes increased gut permeability, leads to systemic and adipose tissue inflammatory changes, and accompanies metabolic dysfunction (Poroyko et al., [2016](#brb31287-bib-0023){ref-type="ref"}). These symptoms are known to be associated with OSAHS‐related metabolic comorbidities, implying that the microbiota--gut--brain axis has a biaxial effect on the development of OSAHS pathology.

Contrastingly, evidence has shown that N1, N3, and REM sleep stages decrease and the N2 sleep stage increases in OSAHS patients (Rosenzweig et al., [2014](#brb31287-bib-0025){ref-type="ref"}). However, a higher N1 percentage, a longer MAD, and a shortened REM sleep stage were revealed in AHI ≥ 15 patients with OSAHS‐induced hypertension (Shao et al., [2018](#brb31287-bib-0026){ref-type="ref"}; Zhan et al., [2018](#brb31287-bib-0033){ref-type="ref"}). Our findings reveal that BP plays a vital role, particularly for SAS, where BP is comprehensively regulated by the peripheral and central systems. Hence, future studies should re‐examine these questions in subgroups of hypertensive and normotensive OSAHS patients to evaluate their general applicability.

In summary, this study initiates a new approach to the study of sleep apnea through a combination of polysomnographic measurements with analysis of enterotypes. Obstructive, central, and mixed apnea indices, N1 and N3 sleep stages, MAD, arousal indices, and mean heart rate were all prominently increased in AHI ≥ 15 patients with the *Prevotella* enterotype. Our results raise the possible association that the microbiota--gut--brain axis operates bidirectionally, with significant impact on the pathogenesis of OSAHS including functions of the gut and brain that eventually contribute to multiple end‐organ morbidities.
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